

Variable	Baseline	Week.4	Week.8	Week.12	Week.16	Week.20	Week.24
<b>CDAI</b>							
<b>All</b>							
N	7	6	5	3	3	2	2
Mean	37.829	30.917	26.3	16.3	25.167	17.7	18.1
Std. Dev.	13.757	11.062	10.774	6.065	10.721	6.364	5.515
Min	17.7	18	13.5	10	16.1	13.2	14.2
1st Qu.	32.45	22.05	19.9	13.4	19.25	15.45	16.15
Median	34	30.5	25.1	16.8	22.4	17.7	18.1
3rd Qu.	42.95	39.325	31.5	19.45	29.7	19.95	20.05
Max	62.3	45	41.5	22.1	37	22.2	22
<b>Anifrolumab</b>							
N	4	3	2	1	1	1	1
Mean	43.55	27.9	22.5	16.8	22.4	13.2	14.2
Std. Dev.	13.343	11.49	12.728	NA	NA	NA	NA
Min	34	18	13.5	16.8	22.4	13.2	14.2
1st Qu.	34	21.6	18	16.8	22.4	13.2	14.2
Median	38.95	25.2	22.5	16.8	22.4	13.2	14.2
3rd Qu.	48.5	32.85	27	16.8	22.4	13.2	14.2
Max	62.3	40.5	31.5	16.8	22.4	13.2	14.2
<b>Placebo</b>							
N	3	3	3	2	2	1	1
Mean	30.2	33.933	28.833	16.05	26.55	22.2	22
Std. Dev.	12.165	12.108	11.274	8.556	14.779	NA	NA
Min	17.7	21	19.9	10	16.1	22.2	22
1st Qu.	24.3	28.4	22.5	13.025	21.325	22.2	22
Median	30.9	35.8	25.1	16.05	26.55	22.2	22
3rd Qu.	36.45	40.4	33.3	19.075	31.775	22.2	22
Max	42	45	41.5	22.1	37	22.2	22

**Supplementary Table 2**

Descriptive statistics for CDAI at each time point over the course of the study.